Ligand id: 6883

Name: panitumumab

No information available.
Summary of Clinical Use
Used to treat EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy.
Mechanism Of Action and Pharmacodynamic Effects
Competitively inhibits the binding of ligands to the epidermal growth factor receptor on both normal and tumour cells. This in turn prevents the receptor autophosphorylation induced by these ligands and the activation of kinases leading to inhibition of cell growth, decreased pro-inflammatory cytokine and vascular growth factor production, and internalisation of the receptor.